Diaceutics, an Irish company that helps patients to receive potentially life-saving medicine through better diagnostic testing, has announced a collaboration with computer hardware manufacturer Lenovo, and chip manufacturer Intel. Using artificial intelligence (AI) to see whether patients can be grouped according to diagnostic test information, the company is hopeful it can help identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics.
Peter Keeling, chief executive officer, Diaceutics said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly innovative technology.
“We can now look at data in a novel way. No longer will we only be making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates.
“This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life changing promise of precision medicine.”
Pictured above: Peter Keeling, CEO, Diaceutics.
Photo credit: Kelvin Boyes
